Bioequivalence Study of Rivastigmine Capsules 1.5 mg of Dr.Reddy's Under Fed Conditions
Status:
Completed
Trial end date:
2004-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this bioequivalence study is to compare the test of Rivastigmine 1.5 mg
Capsules of Dr.Reddy's Laboratories Limited with reference to Exelon 1.5 mg of Novartis in
Healthy Subjects Under Fed Conditions.